---
schema_version: "secwatch.filing_event.v1"
accession: "0001689375-25-000027"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2025-06-03T23:59:59+00:00"
generated_at: "2026-05-20T01:45:32.049878+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Entrada Therapeutics appoints Maha Radhakrishnan, M.D. to board effective June 1, 2025

## Summary
- Maha Radhakrishnan, M.D. appointed as Class III director; board expanded from 6 to 7 members.
- Also appointed to Audit Committee, replacing Kush Parmar, M.D., Ph.D.; Parmar remains chairman.
- Current Executive Partner at Sofinnova Investments; former CMO of Biogen (2019-2024).
- Initial equity award: option to purchase 38,000 shares vesting over 3 years; annual cash fees of $40,000 + $9,000 Audit Committee retainer.
- Appointment takes effect June 1, 2025; serves until 2027 annual meeting.

## SEC filing metadata
- accession: 0001689375-25-000027
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2025-06-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000168937525000027/0001689375-25-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000168937525000027/trda-20250530.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689375-25-000027
- JSON: https://secwatch.observer/filing/0001689375-25-000027.json
- Plain text: https://secwatch.observer/filing/0001689375-25-000027.txt

## Key facts
- Executive change
  Maha Radhakrishnan was appointed as Class III director at Entrada Therapeutics, Inc..
  - Action: appointed
  - Role: Class III director
  source text: On May 30, 2025, the Board of Directors (the “Board”) of Entrada Therapeutics, Inc. (the “Company”) expanded the size of the Board from six to seven directors and appointed Maha Radhakrishnan, M.D. to the Board as a Class III director, to serve until the Company’s annual meeting of stockholders to be held in 2027 or until her successor is duly elected and qualified, in each case effective as of June 1, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1689375/000168937525000027/0001689375-25-000027-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.